AIP variant causing familial prolactinoma.


Journal

Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578

Informations de publication

Date de publication:
Feb 2021
Historique:
accepted: 18 09 2020
pubmed: 4 10 2020
medline: 3 11 2021
entrez: 3 10 2020
Statut: ppublish

Résumé

Pathogenic variants in the aryl hydrocarbon receptor-interacting protein (AIP) gene are increasingly recognised as a cause of familial isolated pituitary adenoma. AIP-associated tumours are most commonly growth hormone (GH) producing. In our cohort of 175 AIP mutation positive patients representing 93 kindreds, 139 (79%) have GH excess, 19 have prolactinoma (17 familial and 2 sporadic cases) and out of the 17 clinically non-functioning tumours 4 were subsequently operated and found to be GH or GH & prolactin immunopositive adenoma. Here we report a family with an AIP variant, in which multiple family members are affected by prolactinoma, but none with GH excess. To our knowledge this is the first reported family with an AIP pathogenic variant to be affected solely by prolactinoma. These data suggest that prolactinoma families represent a small subset of AIP mutation positive kindreds, and similar to young-onset sporadic prolactinomas, AIP screening would be indicated.

Identifiants

pubmed: 33010004
doi: 10.1007/s11102-020-01085-5
pii: 10.1007/s11102-020-01085-5
pmc: PMC7864850
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

48-52

Subventions

Organisme : Medical Research Council
ID : MR/M018539/1
Pays : United Kingdom

Références

J Clin Endocrinol Metab. 2015 Sep;100(9):E1242-54
pubmed: 26186299
J Clin Endocrinol Metab. 2014 Apr;99(4):1122-31
pubmed: 24423289
N Engl J Med. 2011 Jan 6;364(1):43-50
pubmed: 21208107
Eur J Endocrinol. 2013 Mar 15;168(4):533-41
pubmed: 23321498
J Clin Endocrinol Metab. 2020 Jun 1;105(6):
pubmed: 31996917
J Clin Endocrinol Metab. 2010 Nov;95(11):E373-83
pubmed: 20685857
J Clin Endocrinol Metab. 2006 Sep;91(9):3316-23
pubmed: 16787992
Hum Mutat. 2017 Jan;38(1):78-85
pubmed: 27650164
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3539-3544
pubmed: 31125088
J Clin Endocrinol Metab. 2008 Jun;93(6):2390-401
pubmed: 18381572
Neuroendocrinology. 2019;109(1):42-50
pubmed: 30481756

Auteurs

David M Carty (DM)

Department of Diabetes, Endocrinology & Clinical Pharmacology, Glasgow Royal Infirmary, Glasgow, UK. David.Carty@glasgow.ac.uk.

Rachael Harte (R)

Department of Diabetes, Endocrinology & Clinical Pharmacology, Glasgow Royal Infirmary, Glasgow, UK.

Russell S Drummond (RS)

Department of Diabetes, Endocrinology & Clinical Pharmacology, Glasgow Royal Infirmary, Glasgow, UK.

Rebecca Ward (R)

University of Exeter Medical School, Exeter, UK.

Kesson Magid (K)

Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

David Collier (D)

Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Martina Owens (M)

Exeter Genomics Laboratory, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.

Márta Korbonits (M)

Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH